Martingale Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.45M | Buy |
52,434
+2,434
| +5% | +$67.3K | 0.04% | 376 |
|
|
2025
Q1 | $1.11M | Buy |
50,000
+640
| +1% | +$14.2K | 0.03% | 434 |
|
|
2024
Q4 | $976K | Buy |
49,360
+900
| +2% | +$17.8K | 0.02% | 476 |
|
|
2024
Q3 | $1.21M | Buy |
48,460
+3,083
| +7% | +$77K | 0.03% | 418 |
|
|
2024
Q2 | $847K | Hold |
45,377
| – | – | 0.02% | 485 |
|
|
2024
Q1 | $895K | Hold |
45,377
| – | – | 0.02% | 493 |
|
|
2023
Q4 | $796K | Buy |
45,377
+14
| +0% | +$246 | 0.02% | 501 |
|
|
2023
Q3 | $788K | Buy |
45,363
+2
| +0% | +$35 | 0.02% | 508 |
|
|
2023
Q2 | $639K | Buy |
45,361
+1,208
| +3% | +$17K | 0.01% | 563 |
|
|
2023
Q1 | $475K | Buy |
44,153
+1,001
| +2% | +$10.8K | 0.01% | 632 |
|
|
2022
Q4 | $646K | Buy |
43,152
+11
| +0% | +$165 | 0.01% | 573 |
|
|
2022
Q3 | $554K | Buy |
43,141
+3,309
| +8% | +$42.5K | 0.01% | 598 |
|
|
2022
Q2 | $387K | Buy |
39,832
+2,817
| +8% | +$27.4K | 0.01% | 695 |
|
|
2022
Q1 | $369K | Buy |
37,015
+1,401
| +4% | +$14K | 0.01% | 699 |
|
|
2021
Q4 | $420K | Sell |
35,614
-200
| -0.6% | -$2.36K | 0.01% | 679 |
|
|
2021
Q3 | $409K | Buy |
35,814
+21,002
| +142% | +$240K | 0.01% | 703 |
|
|
2021
Q2 | $208K | Hold |
14,812
| – | – | ﹤0.01% | 798 |
|
|
2021
Q1 | $275K | Sell |
14,812
-100
| -0.7% | -$1.86K | ﹤0.01% | 765 |
|
|
2020
Q4 | $265K | Sell |
14,912
-48,600
| -77% | -$864K | ﹤0.01% | 768 |
|
|
2020
Q3 | $974K | Sell |
63,512
-24,095
| -28% | -$370K | 0.01% | 645 |
|
|
2020
Q2 | $2.23M | Buy |
+87,607
| New | +$2.23M | 0.03% | 494 |
|